Eli Lilly | LLY - Capitaux Propres Et Réserves





Capitaux Propres Et Réserves Changement Date
AbbVie USD -5.94B 721M 2026-06
Abbott USD 52.06B 69M 2026-03
ALKERMES USD 1.81B 57.02M 2026-06
Amgen USD 11.69B 2.5B 2026-06
AstraZeneca USD 50.3B 2.96B 2026-06
Baxter International USD 6.21B 163M 2026-06
Biogen USD 18.85B 196.3M 2026-06
Bristol-Myers Squibb USD 22.32B 2.25B 2026-06
Coherus Biosciences USD 60.84M 17.78M 2026-06
Drreddys Laboratories INR 380.46B 376.31B 2026-03
Eli Lilly USD 33.88B 2.68B 2026-06
Gilead Sciences USD 11.74B 11.77B 2026-06
GlaxoSmithKline GBP 17.64B 223M 2026-06
Glaxosmithkline GBP 17.42B 4.64B 2026-03
J&J USD 84.97B 3.78B 2026-06
Medtronic USD 50.07B 1.09B 2026-03
Merck USD 41.93B 3.94B 2026-06
Neurocrine Biosciences USD 3.69B 286.2M 2026-06
Novartis USD 41.95B 3.02B 2026-06
Novartis USD 38.93B 7.2B 2026-03
Novo Nordisk DKK 221.28B 18.21B 2026-06
Perrigo USD 2.52B 17M 2026-06
Pfizer USD 85.19B 4.91B 2026-06
Phibro Animal Health USD 385.48M 23.65M 2026-06
Prestige Brands USD 1.92B 29.2M 2026-06
Regeneron Pharmaceuticals USD 31.71B 287.8M 2026-06
Roche Holding CHF 32.69B 1.11B 2026-06
Sanofi EUR 69.57B 3.24B 2026-06
Sanofi EUR 73.14B 1.43B 2026-03
United Therapeutics USD 6.4B 499.2M 2026-06
Zoetis USD 3.15B 85M 2026-06